drugset / Trial / NCT05412589
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, one-arm, phase II clinical study of intravenous mFOLFOX6 plus Camrelizumab combined with apatinib for CNLC stage III hepatocellular carcinoma
Timeline
- Start
- 2022-06-10
- Primary completion
- 2025-07-31
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Leucovorin | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |